Matrix metalloproteinase 9 mRNA: an early prognostic marker for patients with acute stroke.
To investigate matrix metalloproteinase 9 (MMP9) mRNA as a prognostic marker in stroke. MMP9 mRNA concentrations in 126 stroke patients were analyzed using quantitative reverse transcription-polymerase chain reaction. The normalized MMP9 mRNA concentration was almost 3 times higher in non-survival patients compared to survival patients (P=0.0002); and 1.9-fold higher in patients with post-stroke modified Rankin score (mRS) >2 than patients with mRS≤2 (P<0.05). MMP9 mRNA was a predictor of poor outcome and mortality in stroke.